24th April 2018 As previously disclosed, in July 2017, Kamada submitted a proposed Phase 3 study protocol for Inhaled AAT for treatment of AATD to the FDA. In response, in August 2017, the FDA issued a letter to the Company stating the agency’s continued concerns and questions regarding the safety
Apr 12, 2019 PASADENA, Calif. –(BUSINESS WIRE)–Apr. 12, 2019– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained PASADENA, Calif.–(BUSINESS WIRE)–Apr. 12, 2019– Arrowhead Pharmaceuticals Inc.
The Alpha-1 Foundation hosted the 4th International Research Conference and the 7th Global Patient Congress, April 3-6, 2019, in Dubrovnik, Croatia. The Patient Congress was attended by 160 participants representing 32 countries. The Patient Congress began the evening of April 4th with a welcome reception and a joint dinner with